XFOR x4pharma.com: Multiplikator forward rega marang pendapatan
Global political tensions are hindering international testing of immune therapies and disrupting component supply chains. This X4 Pharmaceuticals (XFOR) projected P/S chart clearly confirms the volatility of market expectations, where the parameter value equals 18.70. However, X4 Pharmaceuticals is developing the unique XOLREMDI to combat WHIM syndrome, and operating within the US legal framework minimizes sanction risks due to the humanitarian status of the developments.
Rincian metrik lan analitis perusahaan X4 Pharmaceuticals, Inc (XFOR)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- rincian valuasi buku bisnis:
- indikator total utang lan likuiditas perusahaan:
Utang Agregat marang Ekuitas X4 Pharmaceuticals|XFOR - Utang jangka dawa marang modal|Rasio tanggungan utang jangka cendhak marang modal X4 Pharmaceuticals|XFOR - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku X4 Pharmaceuticals, Inc|XFOR - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan X4 Pharmaceuticals|Indikator likuiditas cepet x4pharma.com
- data bathi lan kelipatan valuasi:
XFOR - Bathi resik|Proyeksi bathi mangsa ngarep X4 Pharmaceuticals|XFOR - Pangali P/E|Prakiraan rega marang bathi X4 Pharma|XFOR - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan X4 Pharmaceuticals, Inc|XFOR - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) X4 Pharmaceuticals|XFOR - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan x4pharma.com|XFOR - Wutah bathi ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep X4 Pharmaceuticals
- data dodolan lan asil:
Analisis fundamental perusahaan:X4 Pharmaceuticals, Inc. XFOR
For the R&D-intensive business of X4 Pharmaceuticals (XFOR), which focuses on rare immune pathologies, the forward P/S ratio serves as a gauge of market expectations for future commercial success. This metric correlates current market capitalization with projected revenue, reflecting the premium placed on the innovative potential of its team of onco-immunologists. By analyzing the dynamics of the expected P/S, an investor can assess the balance between leadership in clinical phases and the risks of failing to meet sales targets.
Karo sapa X4 Pharmaceuticals saingan
Multiplikator Forward P/S ARGX (argenx)|BioNTech Inc. (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABVX: Multiplikator forward rega marang pendapatan|ADMA (ADMA Corp) - Kapitalisasi marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan Protagonist Therapeutics|Multiplikator forward rega marang pendapatan immunovant.com|KNSA - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan GRFS|ADPT - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S Celldex Corp (CLDX)|Rega forward marang dodolan Aurinia Pharmaceuticals|Multiplikator Forward P/S biocryst.com BCRX|Vera Therapeutics - Multiplikator Forward P/S|DNTH: Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan Pharvaris Corp PHVS|ABCL (AbCellera Corp) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan TRML|Multiplikator Forward P/S precigen.com|Multiplikator Forward P/S PHAR|Multiplikator Forward P/S Nektar Therapeutics Inc (NKTR)|Upstream Bio Corp - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Zenas Corp ZBIO|IMNM (Immunome, Inc.) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|gossamerbio.com (GOSS) - Multiplikator forward rega marang pendapatan|KALV: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Septerna, Inc.|Pieris Pharmaceuticals Inc (PVLA) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S Savara Pharma|RIGL (Rigel Pharmaceuticals) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S anaptysbio.com (ANAB)|Astria Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S enGene Holdings Inc ENGN|RAPT Therapeutics, Inc. - Multiplikator Forward P/S|JBIO: Rasio rega marang prakiraan pendapatan|Aclaris Therapeutics (ACRS) - Rasio rega marang prakiraan pendapatan|KYTX (kyvernatx.com) - Rasio rega marang prakiraan pendapatan|TLSA: Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan Cabaletta Bio Inc. (CABA)|Kapitalisasi marang prakiraan pendapatan Ventyx Bio VTYX|Multiplikator Forward P/S Theratechnologies, Inc (THTX)|Avalo Therapeutics, Inc (AVTX) - Rega mangsa ngarep marang pendapatan|eledon.com - Rasio rega marang prakiraan pendapatan|AGEN (Agenus Inc.) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CLYM: Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan Zura Bio Limited ZURA|ATYR (aTyr Pharmaceuticals) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan Adagene Inc ADAG|Multiplikator Forward P/S Ikena Oncology, Inc.|Shattuck Labs, Inc. (STTK) - Rega forward marang dodolan|Multiplikator Forward P/S equilliumbio.com (EQ)|Multiplikator Forward P/S CNTB (Connect Biopharma Holdings Limited)|Immunic Therapeutics - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan Atara Biotherapeutics Inc (ATRA)|IFRX: Rasio rega marang prakiraan pendapatan|ACET (adicetbio.com) - Multiplikator forward rega marang pendapatan|Celularity (CELU) - Multiplikator Forward P/S|INMB (INmune Bio Corp) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Barinthus Biotherapeutics Corp (BRNS)|Kezar Life Sciences (KZR) - Rega forward marang dodolan|Multiplikator Forward P/S sabbiotherapeutics.com (SABS)|Rasio kapitalisasi marang dodolan sing dikarepake AKTX|Enlivex Therapeutics Ltd - Rasio rega marang prakiraan pendapatan|QTTB: Multiplikator forward rega marang pendapatan|GOVX: Rasio rega marang prakiraan pendapatan|EDSA (Edesa Biotech, Inc.) - Multiplikator forward rega marang pendapatan|Multiplikator forward rega marang pendapatan ibioinc.com|CARM (Carisma Therapeutics Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan XTLB|Kapitalisasi marang prakiraan pendapatan Bolt Biotherapeutics BOLT|Multiplikator Forward P/S hcwbiologics.com (HCWB)|APVO: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AIM - Multiplikator forward rega marang pendapatan|Aditxt Corp (ADTX) - Kapitalisasi marang prakiraan pendapatan|GRI (GRI Bio Inc) - Kapitalisasi marang prakiraan pendapatan|XRTX (XORTX) - Multiplikator forward rega marang pendapatan|Vyome Therapeutics - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Revelation Biosciences|indaptusrx.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S SCNI|CALI (calcimedica.com) - Rega forward marang dodolan|Multiplikator Forward P/S AFMD (Affimed N.V.)|Multiplikator Forward P/S Allakos Inc ALLK|HOOK - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan IGMS (IGM Biosciences, Inc.)|iTeos Therapeutics, Inc. (ITOS) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Ocean Biomedical Inc|TCBP (TC BioPharm (Holdings) PLC) - Multiplikator Forward P/S|Multiplikator Forward P/S Third Harmonic Bio Inc
